• Search History (Register)
  • MeSH Browser
  • [Clear]
    • Canada

Welcome to the international HTA database


Showing [3321 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2014     Medical Advisory Secretariat (MAS) Multiple intravenous infusions. Part II
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Nutritional supplementation for patients with cancer: a review of the clinical effectiveness and guidelines
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Sofosbuvir for the treatment of patients with genotype 4 hepatitis C: a review of the clinical efficacy, cost-effectiveness, and guidelines
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Interventions for non-elderly patients who are high users of ambulatory and emergency medical services: clinical and cost-effectiveness
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Outpatient self-dialysis programs for patients with chronic renal conditions: clinical and cost-effectiveness, safety, and guidelines
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Non-invasive prenatal testing: a review of the cost effectiveness and guidelines
2014     Institute for Clinical Evaluative Sciences (ICES) Health outcomes for better information and care (HOBIC): acute care and home care in Ontario 2013
2014     Institut national d'excellence en sante et en services sociaux (INESSS) [Profile of individuals insured by the public prescription drug insurance plan who have received treatment for hepatitis C (HCV)]
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Foley catheter removal following hip surgery in elderly patients: benefits, harms, and guidelines
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Trientine for treatment of Wilson's disease: clinical and cost-effectiveness, and safety
2014     Institute for Clinical Evaluative Sciences (ICES) Ontario stroke evaluation report 2014: Ontario stroke report cards
2014     Institut national d'excellence en sante et en services sociaux (INESSS) [Use of intravenous immunoglobulins - a review of management strategy experiences and the available evidence]
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) SYMBIS for neurosurgery and spine application: clinical and cost-effectiveness
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Magnetic resonance spectroscopic imaging for prostate disease detection: clinical and cost-effectiveness, and guidelines
2014     Institute for Clinical Evaluative Sciences (ICES) 900,000 days in hospital: The annual impact of smoking, alcohol, diet and physical activity on hospital use in Ontario
2014     Institut national d'excellence en sante et en services sociaux (INESSS) [Stereotactic Body Radiation Therapy (SBRT)]
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Ombitasvir/paritaprevir/ritonavir and dasabuvir
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Next generation DNA sequencing: a review of the cost effectiveness and guidelines
2014     Health Quality Ontario (HQO) Turning for the prevention and management of pressure ulcers: OHTAC Recommendation
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Vitamin D testing in the general population: clinical and cost-effectiveness and guidelines
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Icatibant for patients with type III hereditary angioedema: a review of clinical effectiveness and harms
2014     Health Quality Ontario (HQO) Preventing pressure ulcers: a multisite randomized controlled trial in nursing homes
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Vitamin D toxicity associated with different vitamin D dosing regimens: safety
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Single-use medical devices reprocessed by third party/licenced reprocessors: patient benefits and harms, cost-effectiveness, and guidelines
2014     Health Quality Ontario (HQO) Turning for ulcer reduction (TURN) study: an economic analysis
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Routine ordering of primary pathology examinations in Canada
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Transmission of infectious agents and risk of injury from patient transfer boards in healthcare settings: clinical evidence
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Drug interventions for chronic non-cancer pain: guidelines and recommendations
2014     Health Quality Ontario (HQO) Pre-emptive oral non-steroidal anti-inflammatory drugs or acetaminophen for knee arthroscopy: a rapid review
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Couples therapy for adults experiencing relationship distress: a review of the clinical evidence and guidelines
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) NxStage home hemodialysis use in remote or rural settings with well water: clinical effectiveness, cost-effectiveness, and guidelines
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Non-drug interventions for chronic non-cancer pain: guidelines and recommendations
2014     Health Quality Ontario (HQO) Physiotherapy after knee arthroscopy: a rapid review
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Compression therapy in diabetic foot ulcer management: a review of clinical effectiveness, cost-effectiveness and guidelines
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Flushing intravenous tubing post administration of medications: clinical evidence and guidelines
2014     Health Quality Ontario (HQO) Preoperative shower or bath with antiseptics before knee arthroscopy: a rapid review
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Initiatives to optimize the utilization of laboratory tests
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Corneal cross-linking with riboflavin for keratoconus: update of clinical and cost-effectiveness
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Paracentesis for the removal of peritoneal fluid: guidelines
2014     Health Quality Ontario (HQO) Peripheral nerve blocks for post-operative pain relief after arthroscopic knee ligament reconstruction: a rapid review
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Narcotics, benzodiazepines, stimulants, and gabapentin: policies, initiatives, and practices across Canada, 2014
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Ferumoxytol versus other intravenous iron therapies for anemia: a review of the clinical and cost-effectiveness and guidelines
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Positron emission tomography in neurology and cardiology: a review of guidelines and recommendations
2014     Health Quality Ontario (HQO) Bracing after knee arthroscopy: a rapid review
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) HbA1c testing frequency: a review of the clinical evidence and guidelines
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Antibacterial sutures for wound closure after surgery: a review of clinical and cost-effectiveness and guidelines for use
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Buprenorphine/naloxone (Suboxone) film versus buprenorphine/naloxone tablets for the treatment of opioid addiction: comparative safety
2014     Health Quality Ontario (HQO) Intra-articular analgesia after knee arthroscopy: a rapid review
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Gabapentin for adults with neuropathic pain: a review of the clinical evidence and guidelines
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Non-contact thermometers for detecting fever: a review of clinical effectiveness
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Oncotype DX in women and men with ER-positive HER2-negative early stage breast cancer Who are lymph node-positive: a review of clinical effectiveness and guidelines
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) The use of the electromotive drug administration system in patients with overactive bladder: a review of the clinical effectiveness, safety, and cost-effectiveness
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Mass thermography screening for infection and prevention: a review of the clinical effectiveness
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Compressible non-articulating disc prostheses in adult patients with degenerative disc disease: clinical effectiveness, safety, cost-effectiveness, and guidelines
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Botulinum toxin A for myofascial pain syndrome: a review of the clinical effectiveness
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Long-acting beta2-agonists for chronic obstructive pulmonary disease: safety and harms
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Smart infusion pump use in hospitalized patients: clinical safety and guidelines
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) The use of the electromotive drug administration system in patients with superficial bladder cancer: a review of the clinical effectiveness, safety, and cost-effectiveness
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Transmission of infectious agents from magazines, books, and toys in healthcare settings: clinical evidence and guidelines
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Intranasal versus intravenous administration of anxiolytic or analgesic medications: comparative clinical effectiveness
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Hydroxyethyl starch use for patients with postpartum hemorrhage: a review of clinical effectiveness, safety, and guidelines
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Implementation of extracorporeal membrane oxygenation: clinical evidence
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Intensivist response time to a closed intensive care unit: patient benefits and harms and guidelines
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Debridement procedures for managing diabetic foot ulcers: a review of clinical effectiveness, cost-effectiveness, and guidelines
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Screening tools to identify adults with cognitive impairment associated with dementia: diagnostic accuracy
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) TECNIS® or Acrysof® soft intraocular lenses for patients undergoing cataract surgery: benefits and harms, clinical effectiveness, cost-effectiveness, and guidelines
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Nabilone for non-chemotherapy-associated nausea and weight loss due to medical conditions: a review of the clinical effectiveness and guidelines
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Treatment strategies for patients with renal colic: a review of the comparative clinical and cost-effectiveness
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Wireless device use and patient monitoring equipment in any healthcare delivery setting: a review of safety and guidelines
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Drug therapy for chronic thromboembolic pulmonary hypertension: a review of the comparative clinical effectiveness
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Treatments for constipation: a review of systematic reviews
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Montelukast for sleep apnea: a review of the clinical effectiveness, cost effectiveness, and guidelines
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Infection prevention and control procedures for carbapenemase-producing Enterobacteriaceae: clinical effectiveness and guidelines
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Nicotine replacement therapy for smoking cessation or reduction: a review of the clinical evidence
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Acyclovir versus valacyclovir for herpes virus in children and pregnant women: a review of the clinical evidence and guidelines
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Dexmedetomidine for sedation of patients in the ICU or PICU: review of clinical effectiveness and safety
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Obstetric, neonatal, and child outcomes for women with previous bariatric surgery: a review of the clinical evidence
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Saxagliptin (Onglyza - Bristol-Myers Squibb/AstraZeneca Canada Inc.) indication: type 2 diabetes mellitus
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Essential oil products for disinfection: clinical effectiveness, cost-effectiveness, and guidelines
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Clinical review report. Saxagliptin (Onglyza - Bristol-Myers Squibb/AstraZeneca Canada Inc.) indication: type 2 diabetes mellitus
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Pharmacoeconomic review report. Sofosbuvir (Sovaldi — Gilead Sciences Canada, Inc.) indication: chronic hepatitis C infection
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Pharmacoeconomic review report. Saxagliptin (Onglyza - Bristol-Myers Squibb/AstraZeneca Canada Inc.) indication: type 2 diabetes mellitus
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Clinical review report. Sofosbuvir (Sovaldi — Gilead Sciences Canada, Inc.) indication: chronic hepatitis C infection
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Ulipristal Acetate (Fibristal - Actavis Specialty Pharmaceuticals Co.) indication: uterine fibroids
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Sofosbuvir (Sovaldi — Gilead Sciences Canada, Inc.) indication: chronic hepatitis C infection
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Pharmacoeconomic review report. Ulipristal Acetate (Fibristal - Actavis Specialty Pharmaceuticals Co.) indication: uterine fibroids
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Aripiprazole (Abilify — Bristol-Myers Squibb Canada) new indication: major depressive disorder
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Clinical review report. Ulipristal Acetate (Fibristal - Actavis Specialty Pharmaceuticals Co.) indication: uterine fibroids
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Ustekinumab (Stelara — Janssen Inc.) indication: psoriatic arthritis
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Subsequent entry biologics — emerging trends in regulatory and health technology assessment frameworks
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Aflibercept (Eylea — Bayer Inc.) indication: wet age-related macular degeneration
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Goal setting tools for children: clinical effectiveness and guidelines
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Stiripentol (Diacomit — Biocodex SA) indication: severe myoclonic epilepsy in infancy (Dravet syndrome)
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Maxillary artery ligation for the treatment of cluster or migraine headaches: clinical effectiveness and guidelines
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Clinical review report. Teriflunomide (Aubagio — Genzyme Canada) indication: relapsing-remitting multiple sclerosis
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Hemodialysis chairs versus beds for patients at out-patient clinics: clinical evidence
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Pharmacoeconomic review report. Teriflunomide (Aubagio — Genzyme Canada) indication: relapsing-remitting multiple sclerosis
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Computed tomography-guided brachytherapy treatment in the operating room: clinical effectiveness, cost-effectiveness, and guidelines
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Teriflunomide (Aubagio — Genzyme Canada) indication: relapsing-remitting multiple sclerosis
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Guanfacine hydrochloride extended release (Intuniv XR — Shire Canada Inc.) indication: attention deficit hyperactivity disorder